ACTC1 as an invasion and prognosis marker in glioma

Survival Outcomes in Elderly Patients with Glioblastoma

(2015) D.S. Tsang et al.   CLINICAL ONCOLOGY

Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan

(2015) Yoshitaka NARITA et al.   NEUROLOGIA MEDICO-CHIRURGICA

Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1

(2015) T Que et al.   ONCOGENE

Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis

(2015) Xing Liu et al.   Oncotarget

International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

(2014) David N. Louis et al.   BRAIN PATHOLOGY

Is Supratotal Resection of Glioblastoma in Noneloquent Areas Possible?

(2014) Hugues Duffau   World Neurosurgery

Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma

(2013) Kaisorn L. Chaichana et al.   NEURO-ONCOLOGY

High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma

(2012) Chunzhi Zhang et al.   Journal of Translational Medicine

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

An extent of resection threshold for newly diagnosed glioblastomas

(2011) Nader Sanai et al.   JOURNAL OF NEUROSURGERY

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

HSP90 modulates actin dynamics: Inhibition of HSP90 leads to decreased cell motility and impairs invasion

(2010) Aftab Taiyab et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Actin, a Central Player in Cell Shape and Movement

(2009) T. D. Pollard et al.   SCIENCE

Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer

(2008) L. Toschi et al.   CLINICAL CANCER RESEARCH